目的 探讨鼠神经生长因子联合泼尼松治疗贝尔面瘫的临床效果。方法 选取2017年1月-2018年12月南方医科大学珠江医院收治的贝尔面瘫患者86例，随机分成对照组（43例）和治疗组（43例）。对照组晨起顿服醋酸泼尼松片，起始剂量1 mg/（kg·d），最大剂量≤ 60 mg/d，连用5 d，再于5 d内逐步减量至停用。治疗组在对照组基础上肌内注射注射用鼠神经生长因子，30 μg加入2 mL生理盐水，1次/d。两组患者均治疗10 d。观察两组患者临床疗效，同时比较治疗前后两组患者面神经功能分级、面神经电图参数、血浆内皮素（ET）和一氧化氮（NO）水平及面部残疾指数（FDI）评分。结果 治疗后，对照组和治疗组临床有效率分别为81.4%和95.3%，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者面神经功能Ⅰ级和Ⅱ级例数明显增加（P<0.05），Ⅳ级和Ⅴ级明显减少（P<0.05），且治疗组Ⅰ级和Ⅱ级例数明显多于对照组（P<0.05），Ⅲ级和Ⅳ明显少于对照组（P<0.05）。治疗后，两组口轮匝肌运动传导M波潜伏期均显著缩短（P<0.05），M波波幅显著增加（P<0.05），且治疗组M波潜伏期和M波波幅明显优于对照组（P<0.05）。治疗后，两组血浆ET均显著下降（P<0.05），NO浓度明显升高（P<0.05），且治疗组患者血浆ET、NO浓度明显优于对照组（P<0.05）。治疗后，两组FDI中躯体功能及社会生活功能评分均显著升高（P<0.05），且治疗组患者FDI评分明显高于对照组（P<0.05）。结论 鼠神经生长因子联合泼尼松治疗贝尔面瘫可有效恢复患者面肌功能，改善面神经传导功能，提高生命质量。

Objective To investigate the clinical effect of mouse nerve growth factor combined with prednisone in treatment of Bell's facial paralysis. Methods Patients (86 cases) with Bell's facial paralysis in Zhujiang Hospital of Southern Medical University from January 2017 to December 2018 were randomly divided into control (43 cases) and treatment (43 cases) groups. Patients in the control group were po administered with Linagliptin Tablets at draught, the initial dose was 1 mg/(kg·d), the maximum dose was less than 60 mg/d, and they were treated for 5 d, gradually reduced to discontinuation within 5 days. Patients in the treatment group were intramuscular injection administered with Mouse Nerve Growth Factor for injection on the basis of the control group, 30 μg added into 2 mL normal saline, once daily. Patients in two groups were treated for 10 d. After treatment, the clinical efficacy was evaluated, and the functional grading of facial nerve, the electroencephalogram parameters of facial nerve, ET and NO levels, and FDI scores in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 81.4% and 95.3% respectively, and there were differences between two groups (P<0.05). After treatment, the cases of grade I and grade II of functional grading of facial nerve in two groups were significantly increased (P<0.05), but cases of grade IV and V of functional grading of facial nerve were significantly decreased (P<0.05), and the cases of grade I and grade II in the treatment group were significantly more than those in the control group (P<0.05), but cases of grade III and IV were significantly less than those in the control group (P<0.05). After treatment, the M-wave latency of orbicularis oris muscle motion conduction in two groups were significantly shorten (P<0.05), but M wave amplitude were significantly increased (P<0.05), and latency and amplitude of M-wave in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the plasma ET levels in two groups were significantly decreased (P<0.05), but plasma NO levels were significantly increased (P<0.05), and the ET and NO concentration in the treatment group was significantly better than that in the control group (P<0.05). After treatment, the physical function and social life function score in two groups were significantly increased (P<0.05), and the FDI scores in the treatment group were significantly higher than those in the control group (P<0.05). Conclusion Mouse nerve growth factor combined with prednisone in treatment of Bell's facial paralysis can effectively restore the facial muscle function, improve facial nerve conduction function, and improve the quality of life.